Log in or Sign up for Free to view tailored content for your specialty!
Neurosciences News
Spontaneous intracranial hypotension significantly affects quality of life
SAN DIEGO – Spontaneous intracranial hypotension led to significant physical, mental and quality of life impact for a cohort of those with the condition, according to a speaker at the American Headache Society Annual Scientific Meeting.
FDA clears investigational new drug application to alpha kinase inhibitor for ROSAH syndrome
The FDA has cleared an investigational new drug application for an alpha-kinase 1 inhibitor for clinical evaluation in those with retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache, or ROSAH, syndrome.
Log in or Sign up for Free to view tailored content for your specialty!
Transition to inebilizumab treatment linked to suppression of NMOSD attacks
In patients with neuromyelitis optica spectrum disorder, transition from rituximab to inebilizumab was linked to suppression of attacks over a mean 19 months of treatment, according to research published in Frontiers in Neurology.
Woman presents with unilateral, painless vision loss
A 57-year-old woman was transferred to Lahey Hospital and Medical Center emergency department from a community hospital for an ophthalmology evaluation due to acute, painless vision loss in the left eye upon wakening that morning.
FDA approves Ultomiris for neuromyelitis optica spectrum disorder
The FDA approved Ultomiris for the treatment of adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, according to a press release from Alexion.
Lumevoq shows sustained efficacy, safety 4 years after one-time LHON treatment
Lumevoq demonstrated sustained efficacy and a positive safety profile at 4 years after a one-time injection of the gene therapy in patients with Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.
Uplizna linked to improved outcomes for Hispanic/Latino patients with NMOSD
WEST PALM BEACH, Fla. — Hispanic and Latino individuals with neuromyelitis optica spectrum disorder experienced improved outcomes with Uplizna compared with placebo, according to a poster from ACTRIMS 2024.
Health Canada approves Uplizna for rare form of neuromyelitis optica spectrum disorder
Health Canada has approved Uplizna as a monotherapy for adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 immunoglobulin G seropositive.
VIDEO: Check for mimics of thyroid eye disease
WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Andrew G. Lee, MD, discusses neuro-ophthalmic mimics of thyroid eye disease.
VIDEO: Pupil size, motility deficit may be ‘red flags’ in patients with ptosis
WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye 2024, Andrew G. Lee, MD, overviews some of the major indicators that a patient with ptosis need to be hospitalized.
-
Headline News
A potential new paradigm for treating acute migraine: Timolol nasal spray
November 15, 20245 min read -
Headline News
AI-enabled video of skin on face, hands may detect high blood pressure, diabetes
November 15, 20242 min read -
Headline News
‘Troubling’ data show lack of awareness about lung cancer screening
November 15, 20242 min read
-
Headline News
A potential new paradigm for treating acute migraine: Timolol nasal spray
November 15, 20245 min read -
Headline News
AI-enabled video of skin on face, hands may detect high blood pressure, diabetes
November 15, 20242 min read -
Headline News
‘Troubling’ data show lack of awareness about lung cancer screening
November 15, 20242 min read